Literature DB >> 32946043

Inhalable solid lipid nanoparticles for intracellular tuberculosis infection therapy: macrophage-targeting and pH-sensitive properties.

Cheng Ma1, Mingjun Wu1, Weifen Ye1, Zhengwei Huang1, Xiangyu Ma2, Wenhao Wang1, Wenhua Wang1, Ying Huang3, Xin Pan4, Chuanbin Wu1,5.   

Abstract

Mycobacterium tuberculosis (MTB) is one of the most threatening pathogens for its latent infection in macrophages. The intracellular MTB isolated itself from drugs and could spread via macrophages. Therefore, a mannose-modified macrophage-targeting solid lipid nanoparticle, MAN-IC-SLN, loading the pH-sensitive prodrug of isoniazid (INH), was designed to treat the latent tuberculosis infection. The surface of SLNs was modified by a synthesized 6-octadecylimino-hexane-1,2,3,4,5-pentanol (MAN-SA) to target macrophages, and the modified SLNs showed a higher cell uptake in macrophages (97.2%) than unmodified SLNs (42.4%). The prodrug, isonicotinic acid octylidene-hydrazide (INH-CHO), was synthesized to achieve the pH-sensitive release of INH in macrophages. The INH-CHO-loaded SLNs exhibited a pH-sensitive release profile and accomplished a higher accumulated release in pH 5.5 media (82.63 ± 2.12%) compared with the release in pH 7.4 media (58.83 ± 3.84%). Mycobacterium smegmatis was used as a substitute for MTB, and the MAN-IC-SLNs showed a fourfold increase of intracellular antibiotic efficacy and enhanced macrophage uptake because of the pH-sensitive degradation of INH-CHO and MAN-SA in SLNs, respectively. For the in vivo antibiotic efficacy test, the SLNs group displayed an 83% decrease of the colony-forming unit while the free INH group only showed a 60% decrease. The study demonstrates that macrophage targeting and pH-sensitive SLNs can be used as a promising platform for the latent tuberculosis infection. Graphical Abstract Table of contents: Macrophage-targeting and pH-sensitive solid lipid nanoparticles (SLN) were administrated to the lung via nebulization. Macrophage targeting was achieved by appropriate particle size and surface mannose modification with synthesized MAN-SA. After being swallowed by macrophages, the prodrug, Isonicotinic acid octylidene-hydrazide (INH-CHO), quickly released isoniazid, which was triggered by the intracellular acid environment. The SLNs exhibited higher intracellular antibiotic efficacy due to their macrophage-targeting and pH-sensitive properties.

Entities:  

Keywords:  Latent tuberculosis infection; Mannose modification; Prodrug; Targeting macrophages; pH-sensitive release profile

Mesh:

Substances:

Year:  2020        PMID: 32946043     DOI: 10.1007/s13346-020-00849-7

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  9 in total

1.  Insights into innovative therapeutics for drug-resistant tuberculosis: Host-directed therapy and autophagy inducing modified nanoparticles.

Authors:  Leon J Khoza; Pradeep Kumar; Admire Dube; Patrick H Demana; Yahya E Choonara
Journal:  Int J Pharm       Date:  2022-06-06       Impact factor: 6.510

Review 2.  Current Development of Nano-Drug Delivery to Target Macrophages.

Authors:  Donglin Cai; Wendong Gao; Zhelun Li; Yufeng Zhang; Lan Xiao; Yin Xiao
Journal:  Biomedicines       Date:  2022-05-23

3.  Inhalable Mannosylated Rifampicin-Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy.

Authors:  Juan M Galdopórpora; Camila Martinena; Ezequiel Bernabeu; Jennifer Riedel; Lucia Palmas; Ines Castangia; Maria Letizia Manca; Mariana Garcés; Juan Lázaro-Martinez; Maria Jimena Salgueiro; Pablo Evelson; Nancy Liliana Tateosian; Diego Andres Chiappetta; Marcela Analia Moretton
Journal:  Pharmaceutics       Date:  2022-04-28       Impact factor: 6.525

Review 4.  Nanocarrier-Based Approaches for the Efficient Delivery of Anti-Tubercular Drugs and Vaccines for Management of Tuberculosis.

Authors:  Amarjitsing Rajput; Satish Mandlik; Varsha Pokharkar
Journal:  Front Pharmacol       Date:  2021-12-21       Impact factor: 5.810

5.  Unraveling the publication trends in inhalable nano-systems.

Authors:  Zhengwei Huang; Linjing Wu; Wenhao Wang; Yue Zhou; Xuejuan Zhang; Ying Huang; Xin Pan; Chuanbin Wu
Journal:  J Nanopart Res       Date:  2022-01-07       Impact factor: 2.533

Review 6.  Nanostructures for drug delivery in respiratory diseases therapeutics: Revision of current trends and its comparative analysis.

Authors:  Luis Ángel Ibarra-Sánchez; Ana Gámez-Méndez; Manuel Martínez-Ruiz; Erik Francisco Nájera-Martínez; Brando Alan Morales-Flores; Elda M Melchor-Martínez; Juan Eduardo Sosa-Hernández; Roberto Parra-Saldívar; Hafiz M N Iqbal
Journal:  J Drug Deliv Sci Technol       Date:  2022-03-05       Impact factor: 3.981

Review 7.  Emerging strategies in nanotechnology to treat respiratory tract infections: realizing current trends for future clinical perspectives.

Authors:  Minhua Chen; Zhangxuan Shou; Xue Jin; Yingjun Chen
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

8.  Cooperative coordination-mediated multi-component self-assembly of "all-in-one" nanospike theranostic nano-platform for MRI-guided synergistic therapy against breast cancer.

Authors:  Xiaojie Chen; Xudong Fan; Yue Zhang; Yinghui Wei; Hangsheng Zheng; Dandan Bao; Hengwu Xu; Ji-Gang Piao; Fanzhu Li; Hongyue Zheng
Journal:  Acta Pharm Sin B       Date:  2022-02-26       Impact factor: 14.903

Review 9.  Incorporation of Antibiotics into Solid Lipid Nanoparticles: A Promising Approach to Reduce Antibiotic Resistance Emergence.

Authors:  Lide Arana; Lucia Gallego; Itziar Alkorta
Journal:  Nanomaterials (Basel)       Date:  2021-05-10       Impact factor: 5.076

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.